115 related articles for article (PubMed ID: 1780687)
1. Serum TATI levels and clinical correlation in tumors of the head and neck.
Rayo JI; Garcia-Talavera JR; Martin M; Muñoz A; Del Cañizo A
Scand J Clin Lab Invest Suppl; 1991; 207():33-5. PubMed ID: 1780687
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma.
Goumas PD; Mastronikolis NS; Mastorakou AN; Vassilakos PJ; Nikiforidis GC
ORL J Otorhinolaryngol Relat Spec; 1997; 59(2):106-14. PubMed ID: 9166881
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
Torre GC; Rembado R; Barbetti V; Vigliercio GP; Foglia M; Calabrese A; Corongiu F
Scand J Clin Lab Invest Suppl; 1991; 207():15-8. PubMed ID: 1780684
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor (TATI) in bone diseases.
Rapellino M; Pecchio F; Broggi S; Baldi C; Ricardi G; Libertucci D
Scand J Clin Lab Invest Suppl; 1991; 207():65-6. PubMed ID: 1780696
[TBL] [Abstract][Full Text] [Related]
7. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer.
Pectasides D; Bourazanis J; Economides N; Pozadzidou P; Gogou L; Koutsiouba P; Athanassiou A
Int J Biol Markers; 1993; 8(2):81-7. PubMed ID: 8366300
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease.
Inaudi P; Petrilli S; De Leo V; Bernabei A; Pasqui L; D'Antona N
Scand J Clin Lab Invest Suppl; 1991; 207():11-3. PubMed ID: 1780683
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis.
Medl M; Ogris E; Peters-Engl C; Mierau M; Buxbaum P; Leodolter S
Br J Obstet Gynaecol; 1997 Jan; 104(1):78-81. PubMed ID: 8988701
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
12. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TATI and other markers in solid tumors.
Taccone W; Mazzon W; Belli M
Scand J Clin Lab Invest Suppl; 1991; 207():25-32. PubMed ID: 1780686
[TBL] [Abstract][Full Text] [Related]
14. Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Klockars M; Pettersson T; Fröseth B; Selroos O; Stenman UH
Chest; 1990 Nov; 98(5):1159-64. PubMed ID: 2225961
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G
Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
18. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
Piantino P; Arosaio E
Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G
Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688
[TBL] [Abstract][Full Text] [Related]
20. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]